---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-033922"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T04:13:33.289499+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OPKO reports Q3 net income $24.9M; sells BioReference assets for $237.5M, authorizes $100M buyback

## Summary
- Q3 revenue $173.6M vs $178.6M YoY; net income $24.9M ($0.03/diluted) vs net loss $84.5M ($0.11) in 2023.
- Completed sale of select BioReference Health assets to Labcorp for $237.5M; continues oncology/urology nationwide.
- Entered $250M note purchase agreement with HealthCare Royalty secured by NGENLA profit share payments from Pfizer.
- Board authorized $100M share repurchase program; repurchased 14.9M shares for $23.8M in Q3 and 8.7M more through Nov 6.
- Awarded $51M additional BARDA funding ($26.9M COVID, $24.1M influenza) for ModeX multispecific antibodies.

## SEC filing metadata
- accession: 0001437749-24-033922
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000143774924033922/0001437749-24-033922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000143774924033922/opk20241029_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-033922
- JSON: https://secwatch.observer/filing/0001437749-24-033922.json
- Plain text: https://secwatch.observer/filing/0001437749-24-033922.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.